AELIAN BIOTECHNOLOGY

Aelian Biotechnology allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these screens. The company combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. Aelian Biotechnology's powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs. They utilize and use the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens. Aelian Biotechnology was founded in February 2018 and is headquartered in Vienna, Austria.